A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms Portal
- Sponsors Roche
- 25 Oct 2019 Planned End Date changed from 24 Jun 2022 to 30 Jan 2022.
- 25 Oct 2019 Planned primary completion date changed from 24 Jun 2022 to 31 Mar 2020.
- 30 Oct 2018 According to a Roche media release, based on the results of the LADDER trial, this trial and the pivotal phase III Archway clinical trial were initiated in september 2018.